Annalee Armstrong

Annalee Armstrong, a key figure in Fierce Biotech's annual reports, and Gabrielle Masson, a presenter for the Fierce 15 at NYSE, delve into the fascinating selection process for this year's Fierce 15. They reveal the unique qualities that set these innovative biotech companies apart, from groundbreaking RNA therapies inspired by nature to the rise of women-led firms. The duo also shares insights into collaborations tackling obesity and mental health, showcasing the vibrant landscape of biotech's future.

Fierce Biotech members Annalee Armstrong and Gabrielle Masson discuss the challenges and advancements in cell therapy, including a notable shift towards autoimmune treatments, manufacturing constraints, and the potential impact of CAR-T therapy in various medical fields.